Vera Therapeutics Inc - Ordinary Shares - Class A Aktie News
44,90 $
5,37 %
gestern
Nasdaq,
5. Dezember, 22:05 Uhr
tracken
Vera Therapeutics Inc - Ordinary Shares - Class A Aktie News
Neutral
GlobeNewsWire
●
etwa 5 Stunden alt
BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 42,000 shares of Class A common stock and restricted stock units (RSUs) underlying 21,000 shares of Class A c...
Neutral
Seeking Alpha
●
2 Tage alt
Vera Therapeutics, Inc. (VERA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Positiv
The Motley Fool
●
3 Tage alt
The biotech received a significant boost from a new analyst note. The prognosticator authoring it reiterated his strong buy recommendation on the stock.
Positiv
The Motley Fool
●
9 Tage alt
An analyst expressed his very bullish view on the biotech in a new research note. He reiterated his equivalent of a buy recommendation, and his lofty price target.
Neutral
GlobeNewsWire
●
9 Tage alt
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R.
Neutral
GlobeNewsWire
●
12 Tage alt
BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.
Neutral
GlobeNewsWire
●
26 Tage alt
BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtual...
Neutral
GlobeNewsWire
●
28 Tage alt
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 (p
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
